Curative Biotechnology, Inc. (CUBT)
OID · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Operating Income | -5.0M | -4.4M |
| Net Income | -5.3M | -5.6M |
| Diluted EPS | $-0.01 | $-0.01 |